Literature DB >> 15385922

Clinical trials in AML of the elderly: should we change our methodology?

E Estey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15385922     DOI： 10.1038/sj.leu.2403530

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

Authors:  Ivana Gojo; Anchalee Jiemjit; Jane B Trepel; Alex Sparreboom; William D Figg; Sandra Rollins; Michael L Tidwell; Jacqueline Greer; Eun Joo Chung; Min-Jung Lee; Steven D Gore; Edward A Sausville; James Zwiebel; Judith E Karp
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.

Authors:  Olga Grishina; Claudia Schmoor; Konstanze Döhner; Björn Hackanson; Beate Lubrich; Annette M May; Caroline Cieslik; Michael J Müller; Michael Lübbert
Journal:  BMC Cancer       Date:  2015-05-26       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.